Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 11/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928668 | 0.86 | CYP2C19 (0.58) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL27873188 | 0.82 | CYP2C19 (0.57) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL2565717 | 0.81 | CYP2C19 (0.58) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL1958833 | 0.80 | CYP2C19 (0.61) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL1964662 | 0.80 | CYP2C19 (0.57) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL1960656 | 0.78 | CYP2C19 (0.61) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL1962403 | 0.78 | CYP2C19 (0.61) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL18346376 | 0.78 | CYP2C19 (0.61) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL299699 | 0.78 | CYP2C19 (0.61) | CYP2C19L3MBTL1HTR6MEN1KMT2A | |
| SCHEMBL10142546 | 0.78 | CYP2C19 (0.61) | CYP2C19L3MBTL1HTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102686587-B | Azaindole glucokinase activators | HOFFMANN LA ROCHE | 2015-05-27 | — | — | CN | disclosed |
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CYP2C19 792/4885L3MBTL1 4438/4885HTR6 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.